Insulin

More documents

Recommendations

Info

OADs – 5 classificationsSulphonylureas (SU)Prandial GlucoseRegulators (PGRs)Insulin SecretagoguesBiguanidesInsulin SensitisersThiazolidinediones(TZDs)α-GlucosidaseInhibitors
Oral antidiabetic agents:physiological effectsInsulinsecretagoguesMetforminα-glucosidaseinhibitorsTZDsEffect on FPG/HbA 1c↓↓↓↓Effect on plasma insulin↑ ↓ -↓Effect on LDL-cholesterol - ↓ - ↑Effect on HDL-cholesterol - ↑/- - ↑Effect on triglycerides - ↓ - ↓/-Adapted from DeFronzo RA. Ann Int Med 1999; 131(4):281–303 .
Page 6 and 7: Milestones for Management of Diabet
Page 8 and 9: GLOBAL PROJECTIONS FORTHE DIABETES
Page 10 and 11: ILLNESS• Absence of symptoms• I
Page 13 and 14: UKPDS demonstrated loss of glycemic
Page 15 and 16: UKPDS 35 - Association of glycemia
Page 17 and 18: Lessons from the UKPDS• Too few p
Page 19: Stages to reach and maintain thetar
Page 23 and 24: OHA FOR DIABETESClassEfficacy in Hb
Page 25 and 26: A consensus statement from theAmeri
Page 27 and 28: New Treatment• GLP-1• Amylin an
Page 29 and 30: The Main Incretin• GIP (Glucose-d
Page 31 and 32: GLP-1: regulation and actionsDelaye
Page 33: What does GLP-1 1 do?• Enhance in
Page 36 and 37: Correlation between HbA1c & Plasma
Page 38 and 39: Target for ControlRisk versus benef
Page 40 and 41: • Individualised risk assessment
Page 42 and 43: Steno -2: Microvascular complicatio
Page 44 and 45: Fundamental message• Diabetes man
Page 46 and 47: DOCTORS FACTORS• Not listening to
Page 48 and 49: MULTIDISCIPLINARY CARE• Self care
Page 50: MULTIDISCIPLINARY CARE• Diabetes
Page 53: InterventionsExpecteddecrease inHbA

Insulin

Create successful ePaper yourself

Delete template?

Save as template?